Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa as maintenance therapy in advanced NSCLC (INFORM)
NCT00770588Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Gefitinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival. Started Sep 2008; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00770588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770588.